Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC

Pharmaceutical Investing

Arvinas (NASDAQ:ARVN) has announced the dosing of its first patient in its Phase 1 clinical trial of ARV-110, its oral androgen receptor (AR)-targeted PROTAC protein degrader. As quoted in the press release: The study will evaluate the safety, tolerability, and pharmacokinetics of ARV-110 in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on …

Arvinas (NASDAQ:ARVN) has announced the dosing of its first patient in its Phase 1 clinical trial of ARV-110, its oral androgen receptor (AR)-targeted PROTAC protein degrader.

As quoted in the press release:

The study will evaluate the safety, tolerability, and pharmacokinetics of ARV-110 in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on standard of care therapies. Arvinas believes ARV-110 is the first in a new class of targeted protein degraders to enter human clinical trials and anticipates preliminary data from the study in the second half of 2019.

“With ARV-110 we are harnessing the body’s natural protein disposal system to degrade AR, a key contributor to the progression of prostate cancer,” said John Houston, Ph.D., President and CEO of Arvinas. “Given the promising results seen in preclinical studies, it is our hope that ARV-110 will overcome known mechanisms of resistance to standard of care agents and offer a new treatment option for patients. We believe this is the first time a patient has been treated with this new class of targeted protein degraders and we look forward to furthering our understanding of ARV-110 as a potential treatment for men with mCRPC and the broader field of protein degradation.”

The Phase 1 open-label, dose-escalation clinical trial will assess the safety, tolerability, and pharmacokinetics of ARV-110 and is expected to enroll approximately 28-36 patients with progressive mCRPC. In addition, the study will evaluate the biochemical and clinical activity of ARV-110, by assessing prostate specific antigen (PSA) levels, AR degradation, radiographic measurements of evaluable lesions, and other exploratory markers of disease burden. Additional information on this clinical trial can be found on www.clinicaltrials.gov.

Click here to read the full press release.

The Conversation (0)
×